{"id":"NCT02970162","sponsor":"Catalyst Pharmaceuticals, Inc.","briefTitle":"Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)","officialTitle":"A Phase 3, Double-Blind, Placebo-controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11","primaryCompletion":"2017-10","completion":"2017-10","firstPosted":"2016-11-21","resultsPosted":"2018-12-24","lastUpdate":"2018-12-24"},"enrollment":26,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lambert-Eaton Myasthenic Syndrome"],"interventions":[{"type":"DRUG","name":"Amifampridine Phosphate","otherNames":[]},{"type":"DRUG","name":"Placebo Oral Tablet","otherNames":[]}],"arms":[{"label":"amifampridine phosphate","type":"EXPERIMENTAL"},{"label":"placebo (for amifampridine phosphate)","type":"PLACEBO_COMPARATOR"}],"summary":"This study evaluates the effect of withdrawing amifampridine phosphate treatment from patients with LEMS. One half of the patients will continue to receive amifampridine phosphate and the other half will receive placebo, during this double-blind study.","primaryOutcome":{"measure":"Quantitative Myasthenia Gravis (QMG) Score","timeFrame":"change from baseline in QMG score at end of day 4","effectByArm":[{"arm":"Amifampridine Phosphate","deltaMin":7.8,"sd":4.2},{"arm":"Placebo (for Amifampridine Phosphate)","deltaMin":8.5,"sd":5.43}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0004"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["muscular weakness","myocardial ischemia","fatigue","dry mouth","asthenia"]}}